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Neurodegenerative disorders referred to as tauopathies, which includes Alzheimer’s disease (AD), are characterized
by insoluble deposits of the tau protein within neuron cell bodies and dendritic processes in the brain. Tau is
normally associated with microtubules (MTs) in axons, where it provides MT stabilization and may modulate axonal
transport. However, tau becomes hyperphosphorylated and dissociates from MTs in tauopathies, with evidence of
reduced MT stability and defective axonal transport. This has led to the hypothesis that MT-stabilizing drugs may
have potential for the treatment of tauopathies. Prior studies demonstrated that the brain-penetrant MT-stabilizing
drug, epothilone D, had salutary effects in transgenic (Tg) mouse models of tauopathy, improving MT density and
axonal transport, while reducing axonal dystrophy. Moreover, epothilone D enhanced cognitive performance and
decreased hippocampal neuron loss, with evidence of reduced tau pathology. To date, epothilone D has been the
only non-peptide small molecule MT-stabilizing agent to be evaluated in Tg tau mice. Herein, we demonstrate the
efficacy of another small molecule brain-penetrant MT-stabilizing agent, dictyostatin, in the PS19 tau Tg mouse
model. Although dictyostatin was poorly tolerated at once-weekly doses of 1 mg/kg or 0.3 mg/kg, likely due to
gastrointestinal (GI) complications, a dictyostatin dose of 0.1 mg/kg was better tolerated, such that the majority
of 6-month old PS19 mice, which harbor a moderate level of brain tau pathology, completed a 3-month dosing
study without evidence of significant body weight loss. Importantly, as previously observed with epothilone D,
the dictyostatin-treated PS19 mice displayed improved MT density and reduced axonal dystrophy, with a reduction
of tau pathology and a trend toward increased hippocampal neuron survival relative to vehicle-treated PS19 mice.
Thus, despite evidence of dose-limiting peripheral side effects, the observed positive brain outcomes in
dictyostatin-treated aged PS19 mice reinforces the concept that MT-stabilizing compounds have significant
potential for the treatment of tauopathies.
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Neurodegenerative tauopathies, a group of diseases in-
cluding Alzheimer’s disease (AD), frontotemporal lobar
degeneration (FTLD), progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD) and Pick’s dis-
ease, are characterized by the presence of inclusions
within neurons comprised of the microtubule (MT)-
binding protein, tau [4, 25, 33]. These tau deposits,
referred to as neurofibrillary tangles when found within
neuronal soma and neuritic threads when localized to
dendrites, are thought to lead to the neuron loss that is
characteristic of all tauopathies. In fact, there is a strong
correlation between the density of tau brain pathology and
cognitive status in AD [3, 23, 44] and importantly, tau
mutations can cause inherited forms of FTLD [27, 28].
Tau is a MT-binding protein in neurons, where it
appears to stabilize MT structure [22, 24] and perhaps
also play a role in regulating the MT-binding of motor
proteins involved in axonal transport [21, 41, 42]. In tauo-
pathies, tau becomes hyperphosphorylated due to an
incompletely understood shift in the activity of kinases
and/or phosphatases, with a resulting dissociation of tau
from MTs [1, 2, 9, 36, 43]. Hyperphosphorylation may also
facilitate the misfolding and assembly of tau into fibrils
that form inclusions [2, 37]. The neurodegeneration that
is associated with tau inclusions is thought to result from
gain-of-function toxicities attributable to misfolded tau
oligomers and/or fibrils, as well as loss-of-function resul-
ting from the decreased binding of hyperphosphorylated
tau to MTs, with a resulting destabilization of MTs and/or
impairment of axonal transport [4]. Accordingly, various
therapeutic strategies have been suggested to reduce the
consequences of tau pathology in neurodegenerative
disease [12, 13]. Among these are efforts to compensate
for tau loss-of-function through the utilization of MT-
stabilizing drugs that could “normalize” MTs and axonal
transport in tauopathies. Importantly, there is evidence ofFig. 1 Structures of epothilone D and dictyostatinMT abnormalities in the AD brain [16, 26], as well as in
transgenic mouse models of tauopathy [5, 15, 46]. More-
over, we [15, 46] and others [5] have demonstrated that
the brain-penetrant MT-stabilizing agent, epothilone D
(Fig. 1), significantly improves behavioral and AD-like
brain pathological outcomes in Tg mouse tauopathy
models. This includes increased MT density, reduced
axonal dystrophy, and improved axonal transport with a
salvaging of hippocampal neurons and an apparent reduc-
tion of tau pathology. To date, epothilone D is the only
non-peptide small molecule MT-stabilizing compound
that has been shown to reduce the consequences of tau
inclusion formation in Tg mouse models of tauopathy,
although the octapeptide NAP (also called davunetide)
has been shown to improve outcomes in tau Tg mice
through mechanisms [34] that include MT stabilization
[20, 35].
Recently we reported on another MT-stabilizing agent,
dictyostatin (Fig. 1), which like epothilone D is a natural
product that readily enters the brain upon peripheral ad-
ministration and increases a marker of stable MTs
(acetyl-tubulin) in wild-type mice after a single adminis-
tration at relatively low doses [11]. Interestingly, both
dictyostatin and epothilone D show prolonged brain
retention after clearance from blood, unusual pharmaco-
kinetic behavior which we postulate might provide a
safety and efficacy benefit in the treatment of tauopa-
thies [10, 13]. A long brain half-life permits infrequent
dosing (once weekly in prior studies with epothilone D),
resulting in clearance of the MT-stabilizing drug from
the periphery that potentially minimizes side effects such
as neutropenia and peripheral neuropathy that are typi-
cally observed with drugs of this class when utilized for
the treatment of cancers [6, 17, 18]. Given the simila-
rities in the brain pharmacokinetic and pharmaco-
dynamics properties of epothilone D and dictyostatin,
we examine here the latter MT-stabilizing agent in the
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dictyostatin, like epothilone D, provided benefit to the
central nervous system (CNS) of PS19 mice, impro-
ving MT density and decreasing axonal abnormalities
while reducing tau pathology, with a trend towards in-
creased hippocampal neuron survival. However, unlike
epothilone D, we observed an unexpected dose-limiting
side effect with dictyostatin that led to gastrointestinal
(GI) complications and death of some PS19 mice. The
totality of these data provide further support for the
potential value of small molecule brain-penetrant MT-
stabilizing agents in correcting MT and/or axonal trans-
port deficiencies in AD and related tauopathies, but they
also emphasize that care will be required in identifying
MT-stabilizing drug candidates with the proper balance
of efficacy and safety.Materials and methods
Preparation of dictyostatin
Dictyostatin was synthesized as a white solid (26mg,
0.49mmol) according to reported procedures [38] and
purified by silica gel flash column chromatography
(purity level > 95%, as determined by HPLC and NMR).
All the spectral data (1H-NMR, 13C-NMR, HR-Mass)
were identical to reported data [38].Dictyostatin or vehicle treatment of PS19 and wild-type
mice
A transgene encoding the human T34 tau isoform
(1N4R) containing the P301S mutation found in FTDP-
17, driven by the mouse PrP promoter, was used to
create tau Tg mice [45]. These mice were originally de-
rived on a B6/C3H background, and underwent multiple
generations of backcrossing to yield the congenic B6
PS19 mice used here. In an initial study, 6-month old
male B6 PS19 tau Tg mice received weekly intraperito-
neal (ip) injections with vehicle (DMSO), 1.0 mg/kg
dictyostatin or 0.3 mg/kg dictyostatin. As clear evidence
of intolerance was observed at these doses, a study was
initiated in which 6-month old male PS19 mice (n = 11
per group) were given weekly ip injections of vehicle or
0.1 mg/kg dictyostatin, or a biweekly dose of 0.3 mg/kg
dictyostatin. In addition, age-matched wild-type male
B6 mice (n = 9) received weekly ip administration of
vehicle (DMSO). Animals were monitored for signs of
abnormal behavior or distress, and were weighed weekly
until the completion of study. After 14 weeks of dosing,
surviving animals were sacrificed according to a University
of Pennsylvania IACUC-approved protocol, with blood
collected for analysis of complete blood cell counts. Major
organs were removed for weighing, and brains and optic
nerves (ONs) were harvested for further analyses.Electron Microscopy (EM) evaluation of ON MT density
and axonal dystrophy
Transmission EM was performed on cross-sections of
ONs from vehicle- and dictyostatin-treated PS19 mice
or vehicle-treated B6 wild-type mice essentially as previ-
ously described [15, 46]. Briefly, ONs were post-fixed in
2% glutaraldehyde and 2% paraformaldehyde and then
processed for standard EM [47]. Ultrathin ON sections
were mounted on EM grids and examined using a
JEM1010 electron microscope (Jeol, Peabody, MA) at 80
kV. Cross sections of the entire ON were systematically
sampled at 50,000x and 10,000x magnification, with
MTs and dystrophic axons counted from multiple fields
of 0.035 μm2 and 128 μm2 respectively, from at least
25 photos per ON. The assessors were masked to the
treatment group.
Complete blood counts
Blood from vehicle- or dictyostatin-treated PS19 mice
was analyzed for complete blood cell counts as previ-
ously described (Brunden et al., 2010).
Immunohistochemical analyses
Mice were euthanized by an ip injection of ketamine
hydrochloride (1 mg/10 g) and xylazine ((0.1 mg/10 g),
followed by intracardial perfusion with 20 mL of PBS.
The brains of the mice were then removed and one
hemisphere of each brain was processed as described
previously [15]. Paraffin embedded brain hemispheres
were cut into 6 μm thick sections using a sliding micro-
tome. Immunostained sections that were masked to
treatment identification were imaged using a Lamina
multilabel slide scanner. For analysis of hippocampal
neurons, two matched brain sections (Bregma:−1.70
to −1.82) from vehicle- and dictyostatin-treated PS19 mice
were manually annotated around the CA3 region of the
hippocampus using HALO (Indica Labs, Corrales, NM)
software. To determine neuronal density, sections were
stained with the neuron-specific NeuN antibody (1:500
dilution; Millipore) and the end boundary of the CA3
region was defined by drawing a line from the dentate to
the start of the CA2 region (blue line in Fig. 6a), also using
the demarcation of the end of the CA2 region (black
arrow in Fig. 6a) as a landmark. The NeuN-positive CA3
area was quantified using HALO software after threshold
adjustment to eliminate background signal. Analysis of
tau pathology was performed using two matched brain
sections (Bregma:−1.70 to −1.82) from the vehicle- and
dictyostatin-treated PS19 mice after immunostaining with
the MC1 antibody [31] that recognizes misfolded tau
(1:7000 dilution; kind gift from Dr. Peter Davies). The
HALO algorithm was set to identify MC1-stained areas,
as shown in Fig. 7a, after threshold adjustment to elimi-
nate background signal.
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Combined cortex and hippocampus samples (~40–50 mg)
from frozen hemispheres from vehicle- and dictyostatin-
treated PS19 mice were homogenized in 0.2 ml of RAB
high salt buffer (0.1 M MES, 1 mM EGTA, 0.5 mM
MgSO4, 0.75 M NaCl, 0.02 M NaF, pH 7.0), and the
homogenates were centrifuged at 100,000 × g for 30 min
at 40 C. The supernatant fraction from each sample was
removed and the pellet was re-suspended in 0.1 ml of
RAB buffer, followed by another centrifugation as above.
The supernatant fraction was combined with that from
the first centrifugation, and the pellet was suspended in
0.2 ml of RAB buffer containing 1 M sucrose. The sample
was again centrifuged as above, and the supernatant
fraction which contained myelin was discarded. The pellet
was resuspended in 70 μl of 2% SDS and sonicated,
followed by centrifugation at 100,000 × g for 30 min at
22° C. This SDS supernatant fraction was utilized for
SDS-PAGE analysis and immunoblotting with a rabbit
polyclonal antibody recognizing tau containing an
acetyl modification at lysine residue 280 (TauAcK280)
[29] or the AT8 monoclonal antibody (ThermoFisher) that
recognizes tau that is phosphorylated at serine residue 2026-month old male B6 PS19
Fig. 2 Representative hemisphere brain sections from 6- and 9-month old
matched sections from male PS19 mice were immunostained with the MCor threonine residue 205. The amount of the RAB-
insoluble, SDS-soluble brain sample from each PS19
mouse utilized for SDS-PAGE and immunoblot analysis
was determined by comparing the protein concentrations
in the corresponding RAB buffer soluble samples, with ad-
justment of the SDS-soluble sample volumes so that
equivalent amounts were loaded based on the RAB-
soluble proteins. This method was used since common
housekeeping genes typically utilized for internal gel
normalization partition into the RAB-soluble brain frac-
tion and are not found in the high salt buffer-insoluble
fraction.
Statistics
The statistical method employed for each data set is
described in the Figure legends, as are the group sizes
used for the analyses.
Results
Tolerability findings with dictyostatin-treated PS19 tau Tg
mice
Prior studies from our laboratories demonstrated that
a single 5 mg/kg intraperitoneal (ip) administration of9-month old male B6 PS19
male B6 PS19 months stained for MC1-positive tau pathology. Bregma-
1 antibody and whole hemispheres were imaged. Scale bar = 1 mm
Table 1 Comparison of organ weights (expressed as percentage
of body weight) in PS19 mice treated for 14 weeks with vehicle,
weekly doses of 0.1 mg/kg dictyostatin, or biweekly doses of
0.3 mg/kg dictyostatin
Vehicle Dicytostatin (0.3 mg/kg) Dictyostatin (0.1 mg/kg)
Liver 5.34 +/−0.80 4.90 +/−0.56 5.36 +/−1.20
Spleen 0.28 +/−0.04 0.34 +/−0.07 0.29 +/−0.04
Kidney 1.79 +/−0.14 1.72 +/−0.16 1.65 +/−0.14
Heart 0.60 +/−0.05 0.58 +/−0.02 0.56 +/−0.03
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in brain acetyl-tubulin, a marker of stable MTs [14,
39], in wild-type mice up to 7 days after dosing [11].
Subsequent studies (unpublished) suggested that sin-
gle doses of 0.5–2 mg/kg of dictyostatin could also
elicit a long-lasting increase of brain acetyl-tubulin.
We thus began a study in which 6-month old male
B6 PS19 Tg mice [45], which express full-length four-
repeat tau containing the P301S mutation found in
inherited FTLD, were treated weekly with 1 and 0.3
mg/kg of dictyostatin (ip), with the intent of dosing
until the mice reached 9 months of age. These doses
corresponded to the doses of epothilone D (Fig. 1)
that were found to be highly efficacious in previous
studies with male PS19 mice [15, 46], although the Tg
mice in the prior work were on a B6/C3H hybrid
background, whereas in this study PS19 mice were
back-crossed to obtain a congenic B6 background that
results in somewhat more rapid development of tau
pathology. Thus, B6 PS19 mice have a modest
amount of tau pathology at 6 months of age which
reaches a moderate level my 9 months of age (Fig. 2).
Unexpectedly, the dictyostatin-treated PS19 mice in a
first small cohort (n = 2 per group) showed body
weight loss after 3 weeks, with mortality observed in
all mice in both of the dictyostatin dose groups after
4 weeks of treatment. An autopsy evaluation of the
mice revealed enlargement of the intestines, with an
apparent blockage of GI transit, with no other obviousFig. 3 Dictyostatin doses of 0.3 mg/kg biweekly or 0.1 mg/kg weekly
did not exacerbate body weight loss in 6-month old PS19 mice. Male
6-month old PS19 mice received either biweekly ip injections of 0.3
mg/kg dictyostatin, weekly injections of 0.1 mg/kg dictyostatin, or
weekly injections of vehicle (n = 11/treatment). In addition, wild-type
male 6-month old B6 mice received weekly injections of vehicle.
Body weights were recorded weekly. A total of 6 mice in the 0.3 mg/
kg dictyostatin group and 3 mice in the 0.1 mg/kg dictyostatin group
died before study completion. Error bars represent SEMorgan abnormalities. This was an unexpected finding, as
prior studies with epothilone D did not result in this or
other side effects in either PS19 mice with the B6/
C3H [15, 46] or B6 background (unpublished).
Because of the side effects caused by the weekly 1 and
0.3 mg/kg doses of dictyostatin in PS19 mice, another
study was initiated in which 6-month old male B6 PS19
mice received weekly ip administration of vehicle or 0.1
mg/kg of dictyostatin, or a biweekly dose of 0.3 mg/kg of
dictyostatin (n = 11 for each group), for an intended
study duration of 3 months. In addition, a cohort of
age-matched non-Tg B6 male mice (n = 9) received
vehicle injections once-weekly. At these lower dictyos-
tatin doses, the body weight profile did not differ
significantly between the compound- and vehicle-treated
PS19 mice (Fig. 3), although all PS19 mice lost some
weight over the course of the study in contrast to the
wild-type controls, consistent with frailty in these mice
that presumably results for tau transgene expression.
Notably, 6 mice in the biweekly 0.3 mg/kg dictyostatin
group and 3 mice in the weekly 0.1 mg/kg dictyostatin
group died during the course of the study between weeks
9 and 13, although they did not show evidence of body
weight loss that was significantly greater than the vehicle-
treated PS19 mice. As with the PS19 mice treated with
higher doses of dictyostatin, these mice also showed
evidence of GI complications.
All of the PS19 mice surviving to the study completion
underwent an analysis of major organ weight, and no
significant differences were observed between any of the
mice receiving either of the dictyostatin doses or the
vehicle group (Table 1). Interestingly, no differences
were observed in neutrophil counts or total white blood
cell counts (nor red blood cell counts) in the dictyostatinTable 2 Comparison of blood cell counts in PS19 mice treated
for 14 weeks with vehicle, weekly doses of 0.1 mg/kg dictyostatin,
or biweekly doses of 0.3 mg/kg dictyostatin
WBC (k/μl) Neutrophils (#/μl) RBC (M/μl)
Vehicle 1.99 +/−1.42 516 +/−438 7.81 +/−0.38
Dictyostatin (0.3 mg/kg) 2.74 +/−2.59 764 +/−436 7.92 +/−0.52
Dictyostatin (0.1 mg/kg) 1.86 +/−1.19 860 +/−724 7.60 +/−0.72
WBC white blood cells, RBC red blood cells
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mice (Table 2). As neutropenia is one of the major
complications observed with high doses of MT-stabilizing
agents used for the treatment of cancer [6, 18], these
data suggest that peripheral drug exposure in the biweekly
0.3 mg/kg and weekly 0.1 mg/kg dictyostatin treatment
groups was not sufficient to elicit this side effect. Although
further studies would be required to fully understand the
nature of the GI toxicity observed in the PS19 mice, we
speculate that it may result from inhibition of mucosal
epithelial cell division that has been suggested to be the
cause of chemotherapy-induced enteropathy in patients
receiving anti-cancer drugs [32], including MT-stabilizing
taxanes [19].
Due to the loss of over 50% of the 0.3 mg/kg dictyosta-
tin cohort, efficacy analyses were not conducted with
this treatment group due to the loss of statistical power.
However, all of the 0.1 mg/kg dictyostatin-treated PS19
mice that persisted to study completion (n = 8), asA B
C
Fig. 4 Dictyostatin treatment increased MT density in optic nerves of ag
of cross-sections of optic nerves (a bar = 0.5 μm) from dictyostatin- or v
described [46]. b An expanded imaged showing the grid of hexagons a
counting, only MTs that resided within the hexagon or were on one of
are identified by arrows. c Quantification of MTs/area in the optic nerve
group sizes of 8–11. **, p < 0.01 as determined by one-way ANOVA withwell as the vehicle-treated PS19 and wild-type mice,
underwent analyses of a number of CNS measures, as
described below. No cognitive testing was attempted with
the PS19 mice due to the decreases in group sizes and of
concerns that underlying side effects might compromise
testing outcomes.
Dictyostatin improved brain MT density and reduced
both axonal dystrophy and tau pathology in PS19 tau Tg
mice, with a trend toward lessened hippocampal neuron
loss
We demonstrated previously that aged PS19 mice have a
modest deficit in MT density, as determined through a
comparison of MT counts in cross-sectional electron
microscopic images of optic nerve (ON) sections from
non-Tg littermates and PS19 tau Tg mice [15, 46], which
harbor tau pathology in retinal ganglia cells [15]. In
addition to a small reduction in total MTs, tau Tg mice
have also been shown to have an increase in MTed PS19 mice. MTs were counted in electron micrographs (50,000X)
ehicle-treated aged PS19, or vehicle-treated WT mice, as previously
pplied to optic nerve EM images (bar = 0.1 μm). To avoid repeat
the three indicated borders of each hexagon were counted. MTs
s of mice from each treatment group. Error bars denote SEM, with
a post-hoc Tukey’s multiple comparison test
AB
Fig. 5 Dictyostatin treatment decreased axonal dystrophy in optic
nerves of aged PS19 mice. a A representative electron micrograph
showing an example of a dystrophic axon within the optic nerve
from a study mouse (bar = 0.5 μm). b The number of dystrophic
axons were counted in electron micrographs of cross-sections of
optic nerves from dictyostatin- or vehicle-treated aged PS19 or WT
mice, as previously described [46]. Error bars denote SEM, with group
sizes of 8–11. *, p < 0.05; **, p < 0.01 as determined by one-way
ANOVA with a post-hoc Tukey’s multiple comparison test
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Prior studies revealed that treatment with epothilone D
increased MT density in the PS19 mice to levels that
met or exceeded non-Tg mice of comparable age [15,
46]. A similar analysis was performed on the optic
nerves with the PS19 mice from the 0.1 mg/kg dictyosta-
tin and vehicle treatment groups (Fig. 4), as well as with
vehicle-treated wild-type mice. As summarized in Fig. 4c,
a small reduction of MT density was observed in the PS19
mice relative to age-matched non-Tg mice, and the PS19
mice that were treated with 0.1 mg/kg of dictyostatin
showed a significant increase in MT numbers relative to
the vehicle-treated PS19 mice, mimicking the effect
previously observed with epothilone D [15, 46]. In the
prior reported studies, the epothilone D-mediated im-
provement in MT density within tau tangle-bearing PS19
mice resulted in a significant decrease in the number of
dystrophic retinal ganglion cell axons within the ON. This
was also observed in the dictyostatin-treated PS19 mice,
as axonal dystrophy (Fig. 5a) was significantly reduced
compared to vehicle-treated PS19 mice, approaching the
level observed in the non-Tg mice (Fig. 5b).
One feature of PS19 Tg mice is a loss of hippocampal
neurons, particularly in the CA3 region, upon the devel-
opment of significant tau pathology [45, 46]. To examine
whether any differences were observed in hippocampal
neuron density in the PS19 mice treated with 0.1 mg/kg
dictyostatin compared to vehicle-treated mice, Bregma-
matched fixed brain sections from each mouse were
immunostained with NeuN antibody and the NeuN-
positive area occupied in the CA3 region of the hippo-
campus was quantified. The PS19 mice treated with
dictyostatin had an increase in hippocampal CA3 NeuN
area compared to the vehicle-treated group (Fig. 6),
although this did not reach statistical significance. The
trend in these data, in which only 7 dictyostatin-treated
mice were evaluated due to poorly preserved tissue in
the brain sections from one animal, are consistent with
prior reports of beneficial effects of MT-stabilizing
agents on neuronal survival in tau Tg mice [5, 15, 46],
and further suggest that the low 0.1 mg/kg dose of
dictyostatin provided benefit to the brains of the aged
PS19 mice.
Finally, we and others demonstrated that epothilone
D-treated tau Tg mice have evidence of reduced tau
pathological burden in their brains [5, 46]. An evaluation
of tau pathology in Bregma-matched sections from the
vehicle- and dictyostatin-treated PS19 mice, as deter-
mined after immunostaining with the MC1 antibody
[31] that recognizes misfolded tau, revealed a significant
reduction in pathologic tau in the dictyostatin treatment
group (Fig. 7). To further confirm an effect of dictyosta-
tin on pathological tau, the amount of insoluble tau that
was acetylated at lysine residue 280 (TauAcK280) andphosphorylated at residues Ser202/Thr205 was quan-
tified by fractionation of brain homogenates and subse-
quent immunoblot analysis of the high salt-insoluble
fraction with TauAcK280 and AT8 antibodies, respec-
tively. TauAcK280 is a marker of mature tau tangles
[30], and the PS19 mice treated with 0.1 mg/kg of
dictyostatin had significantly lower levels of insoluble
TauAcK280 than did the PS19 cohort treated with vehicle
(Fig. 8a, b). There was a similar trend toward reduced high
salt-insoluble AT8-tau in the dicytostatin-treated group
(Fig. 8c), although this difference did not reach statistical
AB
Fig. 6 Dictyostatin treatment resulted in a trend towards reduced hippocampal CA3 neuron loss in aged PS19 mice. a Bregma-matched
hemisphere brain sections from dictyostatin- or vehicle-treated aged PS19 mice (two sections/mouse) were immunostained with NeuN
antibody and the area occupied by NeuN staining was determined within the demarcated CA3 region. The end boundary of the CA3 region
was defined by drawing a line from the dentate to the start of the CA2 region (blue line), also using the demarcation of the end of the
CA2 region (black arrow) as a landmark. Representative images with the quantified area are depicted. Scale bar = 1 mm. b A comparison of
the results of NeuN staining in vehicle- and dictyostatin-treated PS19 mice (n = 7 for the dictyostatin group and n = 9 for the vehicle group).
Error bars denote SEM
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and immunoblot data indicate that dictyostatin treatment
resulted in a reduction of tau pathology.
Conclusion
In conclusion, 6-month old PS19 mice with existing
tau pathology treated with a low dose of dictyostatin
(0.1 mg/kg weekly) for 3 months demonstrated improve-
ment in several CNS measures relative to vehicle-treated
PS19 Tg littermates. In this regard, the results observed
after dictyostatin treatment were generally comparable to
those obtained previously with epothilone D. However,
epothilone D is well tolerated at efficacy doses and above
in PS19 Tg mice, whereas these mice showed evidence of
intolerance to dictyostatin.
Discussion
Tau is believed to play an important role in the regulation
of neuronal axonal transport through its association with
MTs. In addition to providing stabilization to MTs [22, 24],
tau may also regulate the binding of kinesin and dynein to
MTs [21, 41, 42], thereby affecting axonal transport. In
neurodegenerative tauopathies, the hyperphosphorylationof tau results in disengagement from MTs such that MT
dynamics and axonal transport are believed to be affected
in ways that could contribute to the tau pathology and
neuronal degeneration observed in these diseases. In this
regard, there is evidence of MT deficits in the AD brain
[16, 26], as well as in Tg mouse models of tauopathy [5, 15,
46, 47]. This led our laboratories to investigate the potential
utility of small molecule MT-stabilizing agents for the treat-
ment of tauopathies. Importantly, we demonstrated previ-
ously that the brain-penetrant MT-stabilizing small
molecule, epothilone D, had salutary effects in both pre-
ventative [15] and interventional [46] studies with PS19 tau
Tg mice that develop extensive tau pathology and neuron
loss with associated memory impairment. The benefits of
epothilone D included improved MT density, reduced
axonal dystrophy, increased axonal transport and, impor-
tantly, reductions in both neuron loss and tau pathology. In
addition, the beneficial effects of epothilone D were asso-
ciated with improved cognitive performance in the PS19
mice, which is significant since clinical improvement is a
requirement for approval of a drug for AD and related
tauopathies. Moreover, these benefits were obtained
with a dose of epothilone D that was ~1/100th the human
AB
Fig. 7 Dictyostatin treatment reduced MC1-positive tau pathology. a Bregma-matched hemisphere brain sections from dictyostatin- or vehicle-treated
aged PS19 mice (two sections/mouse) were immunostained with MC1 antibody, and the total integrated MC1 signal over the section was obtained.
Representative images with quantified areas and relative staining intensity are depicted, where the intensity of staining is shown as a yellow (low OD)
to red (high OD) spectra. Scale bar = 1 mm. b A comparison of the results of MC1 staining in vehicle- and dictyostatin-treated PS19 mice (n = 7 for the
dictyostatin group and n = 10 for the vehicle group). Error bars denote SEM. *, p < 0.05 as determined by a two-tailed t-test
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patients [7], without evidence of any observable side
effects. These positive effects of epothilone D were con-
firmed in two additional tau Tg mouse models [5], where
this MT-stabilizing agent was also shown to mitigate the
MT hyperdynamicity observed in the tauopathy mice.
Subsequent to the publication of these studies, epothi-
lone D (BMS-241027) was tested in a short 9-week trial in
AD patients (ClinicalTrials.gov identifier: NCT01492374)
at doses that were roughly comparable to those used in
the aforementioned mouse studies, when adjusted for
species. Although the results of this small Phase 1b study
have not been published, there has been no additional
reported testing of epothilone D. More recently, a MT-
stabilizing agent from the taxane family, TPI-287, has
entered clinical testing in patients with AD (Clinical
Trials.gov identifier: NCT01966666) and PSP/CBD (Clini
calTrials.gov identifier: CT02133846). To date, there are
no publications on the efficacy of this drug in mouse
models of tauopathy, and the clinical studies with TPI-287
were designed to be 9 weeks in duration. Thus, it will beof interest to see whether changes in disease biomarkers
can be observed after this relatively brief dosing period,
which is much shorter than the typical 18–24 month AD
efficacy trials. Finally, the octapeptide davunetide, which
has reported MT-stabilizing activity [20] and which
improved outcomes in tau Tg mice [35, 40], underwent
testing in a 1-year Phase 2/3 trial in PSP patients in which
the drug was administered intranasally. Unfortunately, the
study results indicated that davunetide was not an effec-
tive treatment for PSP [8].
As the nasally-administered peptide davunetide is the
only MT-stabilizing agent that has undergone exami-
nation in an extended tauopathy clinical trial, there is
merit in identifying and testing new examples that might
serve as drug candidates. Herein, we have examined the
effects of dictyostatin in a 3-month interventional study
utilizing 6-month old PS19 tau Tg mice that harbor a
low level of existing tau pathology which progresses to
become more pronounced as the mice reach 9 months
of age. The original intent was to treat the PS19 mice
with weekly doses of 0.3 mg/kg and 1.0 mg/kg of
AB
C
Fig. 8 Dictyostatin treatment caused a significant reduction of insoluble
TauAcK280. a The high salt buffer-insoluble fraction from combined
cortical and hippocampal homogenates of vehicle- and dictyostatin-
treated aged PS19 mice were analyzed for the amount of TauAcK280 by
immunoblotting. Samples from PS19 mice receiving vehicle (n= 9) or 0.1
mg/kg of dicytostatin (n= 8) were analyzed on two separate gels, with
the densitometric values for TauAcK280 bands from the vehicle and
dictyostatin samples (a) compared and normalized for each gel after
immunoblotting. b A plot of the relative TauAcK280 values in the
vehicle- and dictyostatin-treated PS19 mice. c A similar analysis was
performed in which immunoblots were probed with the AT8 antibody
that recognizes tau that is phosphorylated at Ser202/Thr205. Error bars
denote SEM. *, p< 0.05 as determined by a two-tailed t-test
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the mice, with evidence of GI morbidities. Additional
studies are needed to gain a greater understanding of
this GI complication, but we speculate that dividing in-
testinal epithelial cells may be affected by the MT-
stabilizing agent, as has been reported with anti-cancer
drugs in some oncology patients [32], including those
administered MT-stabilizing taxanes [19].
In response to the GI complications elicited by the
weekly doses of 1.0 and 0.3 mg/kg of dictyostatin, we
initiated a subsequent study in which the compound
was administered biweekly at 0.3 mg/kg, or weekly at a
lower dose of 0.1 mg/kg. Although these dosing regi-
mens did not lead to weight loss that was distinguishable
from PS19 mice receiving vehicle, a significant propor-
tion of the mice in the 0.3 mg/kg dose group and some
mice in the 0.1 mg/kg dose group died 9–13 weeks intothe study. Notably, neutropenia, which is one of the
major side effects in cancer patients taking MT-stabilizing
drugs, was not observed in the PS19 mice receiving either
dictyostatin dose.
As the majority of the PS19 mice receiving weekly
doses of 0.1 mg/kg dictyostatin completed the study,
CNS outcome measures were compared in this treat-
ment group and in vehicle-treated PS19 mice, recogni-
zing that statistical power was reduced due to the loss of
some mice in the dicytostatin group. The PS19 mice
receiving the low dose of dictyostatin showed marked
improvements in several efficacy measures. In particular,
dictyostatin improved MT density with a clear reduction
of axonal dystrophy, resembling the beneficial effects
previously observed with epothilone D [15, 46]. Simi-
larly, dicytostatin treatment led to a trend towards re-
duced hippocampal CA3 neuron loss, and a significant
reduction of MC1- and AcK280-positive tau pathology.
Again, these improvements were similar to those ob-
served with epothilone D, indicating that dictyostatin
has comparable effects to epothilone D in improving
CNS/brain outcomes in this mouse model of tauopathy.
These data provide additional support for the potential
clinical utility of small molecule MT-stabilizing agents
for the treatment of tauopathies, but also reinforce the
importance of achieving efficacy at drug doses that are
well tolerated. We have previously speculated that the
excellent safety profile of epothilone D may result from
the long retention of the drug in the brain and the rela-
tively rapid clearance from blood, such that peripheral
exposures are minimized while sufficient brain concen-
trations are maintained to provide prolonged benefit
[13]. In this regard, dictyostatin shows similarities to
epothilone D, with relatively rapid clearance from blood
with retention in the brain [11]. Thus, the differences in
the toxicity profiles between these two MT-stabilizing
agents was unexpected and may relate to differential
retention in one or more peripheral sites, for example
within intestinal mucosa cells. Alternatively, the dispa-
rities in the safety profiles of epothilone D and dictyos-
tatin may result from differing binding affinities to MTs.
We have demonstrated that dictyostatin is more potent
than epothilone D in a cellular assay of MT-stabilization
[11], and the fact that a very low dose (0.1 mg/kg) of
dictyostatin provided MT stabilization in the brain could
reflect a tight association/slow dissociation from MTs
that also increases the chance for peripheral side effects.
Finally, we cannot exclude the possibility that the GI
complications observed upon dictyostatin dosing are due
to a drug metabolite, or to an off-target interaction un-
related to MT stabilization. Moreover, it is unclear
whether a similar side effect profile would be observed
in humans upon comparable exposure to dictyostatin, as
peripheral neuropathy and neutropenia are the most
Makani et al. Acta Neuropathologica Communications  (2016) 4:106 Page 11 of 12common dose-limiting toxicities observed after treatment
with MT-stabilizing drugs [6, 17, 18] and neutropenia was
not observed at the efficacy dose of dictyostatin. Thus, it
is possible that dictyostatin may still have potential as a
candidate for human tauopathies, although the results
from our studies indicate that additional safety studies
would be required to gain a greater understanding of the
GI complications observed in PS19 tau Tg mice.
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